(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Polycystic Ovarian Syndrome pipeline constitutes 4+ key companies...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - MOUNTAINTODAY.IN - A La Une - 19/Jun 10:56
Hyperuricemia Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest Drug Approvals, Clinical Trials, and Treatment Outlook | Hikma Pharma, Novartis, Pfizer, Roche
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hyperuricemia pipeline constitutes 12+ key companies continuously working towards developing 15+ Hyperuricemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism
Articles similaires
Dravet Syndrome Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies | GW Pharma, Zogenix Inc, Stoke Therapeutics, Takeda Pharma, Supernus Pharma
mountaintoday.in - 20/Jun 10:32
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dravet Syndrome pipeline constitutes 12+ key companies continuously...
Endometrial Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 21/Jun 19:16
DelveInsight’s, “Endometrial Cancer Pipeline Insight 2024” report provides comprehensive insights about 50+ companies...
Pneumococcal Pneumonia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 21/Jun 19:28
DelveInsight’s, “Pneumonia, Pneumococcal Pipeline Insight 2024” report provides comprehensive insights about 12+...
Ulcerative Colitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 21/Jun 19:36
DelveInsight’s, “Ulcerative Colitis Pipeline Insight 2024” report provides comprehensive insights about 70+ companies...
Peritoneal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 26/Jun 19:12
DelveInsight’s, “Peritoneal Cancer Pipeline Insight 2024” report provides comprehensive insights about 55+ companies...
Biliary Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 26/Jun 19:24
DelveInsight’s, “Biliary Tumor Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and...
Hepatic Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 26/Jun 19:28
DelveInsight’s, “Hepatic Tumor Pipeline Insight 2024”report provides comprehensive insights about 75+ companies and 75+...
Primary Biliary Cholangitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 21/Jun 19:24
DelveInsight’s, “Primary Biliary Cholangitis Pipeline Insight 2024” report provides comprehensive insights about 18+...
Advanced Non-Squamous & Squamous NSCLC Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 21/Jun 19:12
DelveInsight’s, “Advanced Non-Squamous & Squamous NSCLC Pipeline Insight, 2024,” report provides comprehensive...
Les derniers communiqués
-
Aucun élément